Radiopharm Receives $5.9M R&D Tax Incentive
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
3 July 2026
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Radiopharm Receives $5.9M R&D Tax Incentive
Sydney, Australia – 3 July 2026 – Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm”
or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative
oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has
received its research and development (R&D) tax refund for the 2025 financial year, totalling
A$.5,885,131, including A$104,475 interest.
The refund is received as part of the Australian Government’s R&D tax incentive, which provides
companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%.
The refund received by Radiopharm will provide important funding for continued development of its
portfolio of radiopharmaceutical products for diagnostic and therapeutic applications.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class
platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in
areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The
company has a pipeline of distinct and highly differentiated platform technologies spanning peptides,
small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase
2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn
more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman
Paul Hopper.
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com
Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
ASX ANNOUNCEMENT
3 July 2026
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
Share your feedback
Discover